25 XP   0   0   10

Protara Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Protara Therapeutics Inc together

PenkeI guess you are interested in Protara Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Protara Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Protara Therapeutics Inc

I send you an email if I find something interesting about Protara Therapeutics Inc.

Quick analysis of Protara Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Protara Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.4%

What is your share worth?

Current worth
$5.98
Expected worth in 1 year
$3.02
How sure are you?
16.2%

+ What do you gain per year?

Total Gains per Share
$-2.95
Return On Investment
-108.1%

For what price can you sell your share?

Current Price per Share
$2.73
Expected price per share
$1.8 - $5.24
How sure are you?
50%

1. Valuation of Protara Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$2.73

Intrinsic Value Per Share

$-26.10 - $-30.26

Total Value Per Share

$-20.12 - $-24.28

2. Growth of Protara Therapeutics Inc (5 min.)




Is Protara Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$68.3m$134.7m-$53.4m-65.7%

How much money is Protara Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$9.9m-$16.2m$6.3m63.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Protara Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#439 / 1019

Most Revenue
#831 / 1019

Most Profit
#554 / 1019

Most Efficient
#275 / 1019

What can you expect buying and holding a share of Protara Therapeutics Inc? (5 min.)

Welcome investor! Protara Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Protara Therapeutics Inc.

What can you expect buying and holding a share of Protara Therapeutics Inc?

First you should know what it really means to hold a share of Protara Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Protara Therapeutics Inc is $2.73. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Protara Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Protara Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.98. Based on the TTM, the Book Value Change Per Share is $-0.74 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.31 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Protara Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.89-32.7%-0.88-32.4%-1.44-52.8%-0.89-32.5%-0.72-26.2%
Usd Book Value Change Per Share-0.76-27.7%-0.74-27.0%-1.31-47.9%0.217.7%0.165.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.76-27.7%-0.74-27.0%-1.31-47.9%0.217.7%0.165.9%
Usd Price Per Share1.88-2.27-3.42-7.84-7.28-
Price to Earnings Ratio-0.52--0.65--0.91--2.47--2.58-
Price-to-Total Gains Ratio-2.48--3.14--4.30--3.78--8.78-
Price to Book Ratio0.31-0.32-0.29-0.94-1.15-
Price-to-Total Gains Ratio-2.48--3.14--4.30--3.78--8.78-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.73
Number of shares366
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.740.21
Usd Total Gains Per Share-0.740.21
Gains per Quarter (366 shares)-270.1476.64
Gains per Year (366 shares)-1,080.54306.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1081-10910307297
20-2161-21720613604
31-3242-32530920911
41-4323-4334012261218
51-5404-5415015331525
61-6484-6496018391832
71-7565-7577021462139
82-8646-8658024522446
92-9727-9739027592753
102-10807-10820030653060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.036.00.02.7%1.036.00.02.7%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%6.031.00.016.2%6.031.00.016.2%
Dividend per Share2.00.02.050.0%2.00.010.016.7%2.00.018.010.0%2.00.035.05.4%2.00.035.05.4%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%6.031.00.016.2%6.031.00.016.2%

Fundamentals of Protara Therapeutics Inc

About Protara Therapeutics Inc

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-04-12 19:38:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Protara Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Protara Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Protara Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Protara Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y--436.8%+436.8%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Protara Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Protara Therapeutics Inc to the Biotechnology industry mean.
  • -12.9% Return on Assets means that Protara Therapeutics Inc generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Protara Therapeutics Inc:

  • The MRQ is -12.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.9%TTM-11.0%-2.0%
TTM-11.0%YOY-12.8%+1.8%
TTM-11.0%5Y-8.5%-2.4%
5Y-8.5%10Y-10.6%+2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.9%-13.6%+0.7%
TTM-11.0%-12.9%+1.9%
YOY-12.8%-11.9%-0.9%
5Y-8.5%-14.2%+5.7%
10Y-10.6%-16.2%+5.6%
1.1.3. Return on Equity

Shows how efficient Protara Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Protara Therapeutics Inc to the Biotechnology industry mean.
  • -15.0% Return on Equity means Protara Therapeutics Inc generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Protara Therapeutics Inc:

  • The MRQ is -15.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.0%TTM-12.5%-2.5%
TTM-12.5%YOY-14.0%+1.5%
TTM-12.5%5Y-9.6%-2.8%
5Y-9.6%10Y-12.0%+2.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.0%-17.0%+2.0%
TTM-12.5%-16.1%+3.6%
YOY-14.0%-15.4%+1.4%
5Y-9.6%-20.0%+10.4%
10Y-12.0%-21.1%+9.1%

1.2. Operating Efficiency of Protara Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Protara Therapeutics Inc is operating .

  • Measures how much profit Protara Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Protara Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Protara Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y--475.2%+475.2%
10Y--624.7%+624.7%
1.2.2. Operating Ratio

Measures how efficient Protara Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Protara Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y-5.675-5.675
10Y-7.857-7.857

1.3. Liquidity of Protara Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Protara Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 11.17 means the company has $11.17 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Protara Therapeutics Inc:

  • The MRQ is 11.173. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.626. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.173TTM13.626-2.453
TTM13.626YOY25.559-11.933
TTM13.6265Y22.644-9.018
5Y22.64410Y18.838+3.805
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.1733.930+7.243
TTM13.6264.251+9.375
YOY25.5595.436+20.123
5Y22.6446.045+16.599
10Y18.8386.363+12.475
1.3.2. Quick Ratio

Measures if Protara Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Protara Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 14.93 means the company can pay off $14.93 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Protara Therapeutics Inc:

  • The MRQ is 14.932. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 20.357. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.932TTM20.357-5.426
TTM20.357YOY40.962-20.605
TTM20.3575Y29.032-8.675
5Y29.03210Y25.184+3.849
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.9323.629+11.303
TTM20.3574.065+16.292
YOY40.9625.397+35.565
5Y29.0325.993+23.039
10Y25.1846.277+18.907

1.4. Solvency of Protara Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Protara Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Protara Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13 means that Protara Therapeutics Inc assets are financed with 13.5% credit (debt) and the remaining percentage (100% - 13.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Protara Therapeutics Inc:

  • The MRQ is 0.135. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.120. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.135TTM0.120+0.015
TTM0.120YOY0.070+0.050
TTM0.1205Y0.080+0.040
5Y0.08010Y0.089-0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1350.332-0.197
TTM0.1200.334-0.214
YOY0.0700.268-0.198
5Y0.0800.366-0.286
10Y0.0890.390-0.301
1.4.2. Debt to Equity Ratio

Measures if Protara Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Protara Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 15.6% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Protara Therapeutics Inc:

  • The MRQ is 0.156. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.136. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.156TTM0.136+0.020
TTM0.136YOY0.075+0.061
TTM0.1365Y0.090+0.046
5Y0.09010Y0.102-0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1560.381-0.225
TTM0.1360.390-0.254
YOY0.0750.334-0.259
5Y0.0900.434-0.344
10Y0.1020.466-0.364

2. Market Valuation of Protara Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Protara Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Protara Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.52 means the investor is paying $-0.52 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Protara Therapeutics Inc:

  • The EOD is -0.763. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.524. Based on the earnings, the company is expensive. -2
  • The TTM is -0.651. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.763MRQ-0.524-0.239
MRQ-0.524TTM-0.651+0.126
TTM-0.651YOY-0.909+0.258
TTM-0.6515Y-2.465+1.814
5Y-2.46510Y-2.584+0.119
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.763-2.315+1.552
MRQ-0.524-2.560+2.036
TTM-0.651-2.664+2.013
YOY-0.909-4.122+3.213
5Y-2.465-6.258+3.793
10Y-2.584-6.108+3.524
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Protara Therapeutics Inc:

  • The EOD is -0.897. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.616. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 8.814. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-0.897MRQ-0.616-0.281
MRQ-0.616TTM8.814-9.431
TTM8.814YOY-1.510+10.325
TTM8.8145Y-1.488+10.303
5Y-1.48810Y-2.810+1.322
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.897-3.067+2.170
MRQ-0.616-3.251+2.635
TTM8.814-3.545+12.359
YOY-1.510-5.595+4.085
5Y-1.488-8.315+6.827
10Y-2.810-8.708+5.898
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Protara Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.31 means the investor is paying $0.31 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Protara Therapeutics Inc:

  • The EOD is 0.457. Based on the equity, the company is cheap. +2
  • The MRQ is 0.314. Based on the equity, the company is cheap. +2
  • The TTM is 0.315. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.457MRQ0.314+0.143
MRQ0.314TTM0.315-0.001
TTM0.315YOY0.289+0.026
TTM0.3155Y0.935-0.620
5Y0.93510Y1.152-0.217
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4571.905-1.448
MRQ0.3142.111-1.797
TTM0.3152.095-1.780
YOY0.2892.836-2.547
5Y0.9353.443-2.508
10Y1.1523.794-2.642
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Protara Therapeutics Inc.

3.1. Institutions holding Protara Therapeutics Inc

Institutions are holding 38.926% of the shares of Protara Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Opaleye Management Inc23.69221.3426269259400
2023-09-30Vanguard Group Inc3.7626042761200
2023-09-30Boxer Capital LLC1.8410.018620922700
2023-09-30Baker Bros Advisors LP1.75690.001919967100
2023-12-31Ikarian Capital, LLC1.66010.03318866400
2023-12-31Privium Fund Management (UK) Ltd1.05350.152411973000
2023-12-31Renaissance Technologies Corp0.99690.00031133005320088.5191
2023-09-30Geode Capital Management, LLC0.6909078518-4902-5.8763
2023-12-31Bridgeway Capital Management, LLC0.56310.00266400000
2023-09-30Susquehanna International Group, LLP0.3077034971349710
2023-09-30BlackRock Inc0.3045034602-1636-4.5146
2023-09-30State Street Corporation0.271903090000
2023-12-31Two Sigma Advisers, LLC0.23770.000127018-800-2.8758
2023-12-31Two Sigma Investments LLC0.22130.000125145-2200-8.0453
2023-09-30Citadel Advisors Llc0.194802214312135121.253
2023-09-30Northern Trust Corp0.181102058700
2023-12-31BOOTHBAY FUND MANAGEMENT, LLC0.1660.00091886400
2023-09-30Millennium Management LLC0.1588018047-6501-26.4828
2023-09-30Bank of New York Mellon Corp0.157601790700
2023-12-31Assenagon Asset Management SA0.13930.00011583100
Total 38.35791.55264359331+84267+1.9%

3.2. Funds holding Protara Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.48650.000128430100
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.23030.000614066800
2024-02-29Fidelity Extended Market Index0.41730.000647719-231-0.4818
2023-12-31Bridgeway Ultra-Small Company Market0.34280.03953920000
2023-12-31Bridgeway Ultra-Small Company0.21690.05352480000
2024-03-28iShares Micro-Cap ETF0.18380.009221013249113.4489
2024-02-29Fidelity Series Total Market Index0.1150.00011314800
2024-02-29Fidelity Total Market Index0.10230.00011170100
2023-12-31NT Ext Equity Mkt Idx Fd - L0.07170.0003819700
2023-12-31Northern Trust Extended Eq Market Idx0.07170.0003819700
2023-12-31SSgA U.S. Extended Market Index Class I0.06820.0005780000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06610.0002755800
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05310.00026070110.1815
2024-03-31State St US Extended Mkt Indx NL Cl C0.03060.0007350000
2024-02-29Spartan Extended Market Index Pool E0.02610.000529812318.4
2024-02-29Spartan Total Market Index Pool E0.02560292500
2024-02-29Vanguard U.S. Eq Idx £ Acc0.02310.0001264300
2023-12-31SSgA U.S. Total Market Index Strategy0.01970.00012250-52-2.2589
2024-02-29Dimensional Global Core Equity USD Acc0.01940.0002221600
2024-02-291290 VT Micro Cap K0.01530.0054175550.2857
Total 5.58550.1122638642+2455+0.4%

3.3. Insider Transactions

Insiders are holding 16.594% of the shares of Protara Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-09-14Opaleye Management Inc.BUY166003.98
2022-08-11Jesse SheffermanBUY90653.84
2022-06-30Luke M BesharBUY100003.1
2022-04-07Opaleye Management Inc.BUY23454.74
2022-03-14Luke M BesharBUY100004.25
2022-03-10Luke M BesharBUY100004.46
2022-01-28Opaleye Management Inc.BUY240314.96
2021-12-29Opaleye Management Inc.BUY45006.98
2021-12-27Opaleye Management Inc.BUY367006.53
2021-12-23Opaleye Management Inc.BUY13006.6
2021-12-20Opaleye Management Inc.BUY7036.49
2021-12-16Opaleye Management Inc.BUY75636.41
2021-11-17Opaleye Management Inc.BUY91186.98
2021-11-04Opaleye Management Inc.BUY65576.5
2021-06-10Martin Sebastian OlivoBUY989310.1

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Protara Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.755-0.738-2%-1.308+73%0.209-461%0.161-568%
Book Value Per Share--5.9757.112-16%11.784-49%9.461-37%6.995-15%
Current Ratio--11.17313.626-18%25.559-56%22.644-51%18.838-41%
Debt To Asset Ratio--0.1350.120+13%0.070+93%0.080+68%0.089+51%
Debt To Equity Ratio--0.1560.136+14%0.075+106%0.090+73%0.102+52%
Dividend Per Share---0.000-100%-0%0.000-100%0.000-100%
Eps---0.894-0.884-1%-1.442+61%-0.886-1%-0.716-20%
Free Cash Flow Per Share---0.761-0.675-11%-0.581-24%-0.616-19%-0.545-28%
Free Cash Flow To Equity Per Share---0.761-0.677-11%-0.585-23%0.257-397%0.224-440%
Gross Profit Margin--1.0101.003+1%1.000+1%1.001+1%1.000+1%
Intrinsic Value_10Y_max---30.259--------
Intrinsic Value_10Y_min---26.098--------
Intrinsic Value_1Y_max---2.750--------
Intrinsic Value_1Y_min---2.701--------
Intrinsic Value_3Y_max---8.478--------
Intrinsic Value_3Y_min---8.090--------
Intrinsic Value_5Y_max---14.466--------
Intrinsic Value_5Y_min---13.408--------
Market Cap31214274.000+31%21439518.38025912135.095-17%39103596.000-45%89666203.529-76%83281048.908-74%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.457+31%0.3140.3150%0.289+8%0.935-66%1.152-73%
Pe Ratio-0.763-46%-0.524-0.651+24%-0.909+73%-2.465+370%-2.584+393%
Price Per Share2.730+31%1.8752.266-17%3.420-45%7.842-76%7.284-74%
Price To Free Cash Flow Ratio-0.897-46%-0.6168.814-107%-1.510+145%-1.488+142%-2.810+356%
Price To Total Gains Ratio-3.615-46%-2.483-3.137+26%-4.299+73%-3.778+52%-8.779+254%
Quick Ratio--14.93220.357-27%40.962-64%29.032-49%25.184-41%
Return On Assets---0.129-0.110-15%-0.128-1%-0.085-34%-0.106-18%
Return On Equity---0.150-0.125-17%-0.140-6%-0.096-36%-0.120-20%
Total Gains Per Share---0.755-0.738-2%-1.308+73%0.209-461%0.162-568%
Usd Book Value--68321000.00081317500.000-16%134738500.000-49%108179406.850-37%79981138.838-15%
Usd Book Value Change Per Share---0.755-0.738-2%-1.308+73%0.209-461%0.161-568%
Usd Book Value Per Share--5.9757.112-16%11.784-49%9.461-37%6.995-15%
Usd Dividend Per Share---0.000-100%-0%0.000-100%0.000-100%
Usd Eps---0.894-0.884-1%-1.442+61%-0.886-1%-0.716-20%
Usd Free Cash Flow---8700000.000-7719000.000-11%-6644250.000-24%-7041812.650-19%-6225898.730-28%
Usd Free Cash Flow Per Share---0.761-0.675-11%-0.581-24%-0.616-19%-0.545-28%
Usd Free Cash Flow To Equity Per Share---0.761-0.677-11%-0.585-23%0.257-397%0.224-440%
Usd Market Cap31214274.000+31%21439518.38025912135.095-17%39103596.000-45%89666203.529-76%83281048.908-74%
Usd Price Per Share2.730+31%1.8752.266-17%3.420-45%7.842-76%7.284-74%
Usd Profit---10221000.000-9933250.000-3%-16274000.000+59%-9689387.900-5%-7760993.459-24%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.755-0.738-2%-1.308+73%0.209-461%0.162-568%
 EOD+5 -3MRQTTM+5 -27YOY+10 -205Y+4 -2810Y+4 -28

4.2. Fundamental Score

Let's check the fundamental score of Protara Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.763
Price to Book Ratio (EOD)Between0-10.457
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than114.932
Current Ratio (MRQ)Greater than111.173
Debt to Asset Ratio (MRQ)Less than10.135
Debt to Equity Ratio (MRQ)Less than10.156
Return on Equity (MRQ)Greater than0.15-0.150
Return on Assets (MRQ)Greater than0.05-0.129
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Protara Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.225
Ma 20Greater thanMa 503.623
Ma 50Greater thanMa 1003.718
Ma 100Greater thanMa 2002.823
OpenGreater thanClose2.820
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets78,954
Total Liabilities10,633
Total Stockholder Equity68,321
 As reported
Total Liabilities 10,633
Total Stockholder Equity+ 68,321
Total Assets = 78,954

Assets

Total Assets78,954
Total Current Assets68,705
Long-term Assets10,249
Total Current Assets
Cash And Cash Equivalents 39,586
Short-term Investments 25,994
Net Receivables 242
Other Current Assets 2,883
Total Current Assets  (as reported)68,705
Total Current Assets  (calculated)68,705
+/-0
Long-term Assets
Property Plant Equipment 6,560
Long-term Assets Other 2,944
Long-term Assets  (as reported)10,249
Long-term Assets  (calculated)9,504
+/- 745

Liabilities & Shareholders' Equity

Total Current Liabilities6,149
Long-term Liabilities4,484
Total Stockholder Equity68,321
Total Current Liabilities
Short-term Debt 983
Accounts payable 2,434
Other Current Liabilities 2,732
Total Current Liabilities  (as reported)6,149
Total Current Liabilities  (calculated)6,149
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt4,484
Long-term Liabilities  (as reported)4,484
Long-term Liabilities  (calculated)4,484
+/- 0
Total Stockholder Equity
Common Stock11
Retained Earnings -200,384
Accumulated Other Comprehensive Income -31
Other Stockholders Equity 268,725
Total Stockholder Equity (as reported)68,321
Total Stockholder Equity (calculated)68,321
+/-0
Other
Capital Stock11
Cash and Short Term Investments 65,580
Common Stock Shares Outstanding 11,365
Liabilities and Stockholders Equity 78,954
Net Debt -34,119
Net Invested Capital 68,321
Net Working Capital 62,556
Property Plant and Equipment Gross 7,384
Short Long Term Debt Total 5,467



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
> Total Assets 
24,179
84,800
80,930
76,580
72,280
67,540
61,340
55,660
49,400
43,520
36,020
33,630
48,560
43,980
38,510
27,850
27,405
23,521
18,060
11,600
52,652
6,975
70,096
63,256
198,907
203,157
192,413
188,892
180,697
172,596
161,256
154,884
148,591
113,290
106,405
95,141
88,467
78,954
78,95488,46795,141106,405113,290148,591154,884161,256172,596180,697188,892192,413203,157198,90763,25670,0966,97552,65211,60018,06023,52127,40527,85038,51043,98048,56033,63036,02043,52049,40055,66061,34067,54072,28076,58080,93084,80024,179
   > Total Current Assets 
21,920
84,600
80,730
75,790
71,380
66,610
60,440
54,910
48,720
42,760
35,390
33,020
47,980
43,480
38,030
27,510
27,083
23,236
17,933
11,495
41,957
6,975
39,682
32,849
167,115
169,435
87,697
87,819
95,695
93,112
90,689
101,091
98,667
86,146
94,616
84,265
77,813
68,705
68,70577,81384,26594,61686,14698,667101,09190,68993,11295,69587,81987,697169,435167,11532,84939,6826,97541,95711,49517,93323,23627,08327,51038,03043,48047,98033,02035,39042,76048,72054,91060,44066,61071,38075,79080,73084,60021,920
       Cash And Cash Equivalents 
3,239
68,840
9,780
16,820
35,980
40,030
24,060
34,190
26,680
36,390
34,130
18,390
19,990
21,170
25,360
12,490
18,225
19,371
16,763
10,813
41,861
6,181
36,069
29,971
165,905
168,598
58,201
46,836
40,742
35,724
25,436
33,815
47,498
24,127
21,035
33,978
33,768
39,586
39,58633,76833,97821,03524,12747,49833,81525,43635,72440,74246,83658,201168,598165,90529,97136,0696,18141,86110,81316,76319,37118,22512,49025,36021,17019,99018,39034,13036,39026,68034,19024,06040,03035,98016,8209,78068,8403,239
       Short-term Investments 
18,447
14,760
69,740
57,920
34,570
25,230
35,330
19,490
20,300
4,930
4,930
13,360
27,440
20,970
11,460
13,970
7,987
2,496
2,496
0
0
0
0
0
0
0
26,144
37,830
53,016
55,505
62,155
64,643
48,819
60,243
65,575
46,382
40,266
25,994
25,99440,26646,38265,57560,24348,81964,64362,15555,50553,01637,83026,14400000002,4962,4967,98713,97011,46020,97027,44013,3604,9304,93020,30019,49035,33025,23034,57057,92069,74014,76018,447
       Net Receivables 
0
0
0
685
0
706
693
383
276
0
0
300
300
0
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
634
528
487
380
486
491
344
279
242
242279344491486380487528634000000000000100000300300002763836937060685000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,215
2,566
-487
0
1,163
-491
3,560
-279
0
0-2793,560-4911,1630-4872,5661,21500000000000000000000000000000
   > Long-term Assets 
2,259
200
200
790
900
930
900
750
680
760
630
610
580
500
480
340
322
285
127
105
10,695
0
30,415
30,407
31,792
33,722
104,716
101,073
85,002
79,484
70,567
53,793
49,924
27,144
11,789
10,876
10,654
10,249
10,24910,65410,87611,78927,14449,92453,79370,56779,48485,002101,073104,71633,72231,79230,40730,415010,6951051272853223404805005806106307606807509009309007902002002,259
       Property Plant Equipment 
86
80
80
100
220
220
210
370
400
370
340
310
280
260
240
220
200
263
105
83
429
0
1,047
1,040
761
1,240
1,498
9,417
9,142
8,890
8,629
8,371
8,168
7,869
7,565
7,250
6,968
6,560
6,5606,9687,2507,5657,8698,1688,3718,6298,8909,1429,4171,4981,2407611,0401,047042983105263200220240260280310340370400370210220220100808086
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,966
0
29,367
29,367
29,367
29,517
29,517
29,517
29,517
29,517
29,517
29,517
29,517
0
0
0
0
0
0000029,51729,51729,51729,51729,51729,51729,51729,51729,36729,36729,36709,96600000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
745
70,824
60,378
44,652
39,467
30,889
14,349
10,760
17,886
2,893
0
0
0
0002,89317,88610,76014,34930,88939,46744,65260,37870,8247450000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
0
0
0
0
0
0
0
0
0
0
29,517
29,517
0
0
0
0
0
0000029,51729,517000000000030000000000000000000000
       Long-term Assets Other 
2,173
120
120
690
680
710
690
380
280
390
290
300
300
240
240
120
122
22
22
22
10,695
0
392
384
1,664
2,965
2,877
1,761
1,691
1,610
1,532
1,556
1,479
1,389
1,331
2,881
2,941
2,944
2,9442,9412,8811,3311,3891,4791,5561,5321,6101,6911,7612,8772,9651,664384392010,6952222221221202402403003002903902803806907106806901201202,173
> Total Liabilities 
14,561
2,340
2,630
2,820
3,250
4,130
3,590
4,740
4,880
5,080
3,020
4,140
9,090
9,240
9,020
2,230
2,534
3,078
3,370
2,123
739
583
5,354
3,825
4,281
3,914
4,287
10,487
10,291
10,682
9,021
9,426
9,413
11,207
11,637
9,916
11,511
10,633
10,63311,5119,91611,63711,2079,4139,4269,02110,68210,29110,4874,2873,9144,2813,8255,3545837392,1233,3703,0782,5342,2309,0209,2409,0904,1403,0205,0804,8804,7403,5904,1303,2502,8202,6302,34014,561
   > Total Current Liabilities 
2,658
2,340
2,630
2,770
3,170
4,130
3,590
4,740
4,880
5,080
3,020
4,140
9,090
9,240
9,020
2,230
2,534
3,078
3,370
2,123
739
583
4,968
3,447
3,887
2,915
3,313
3,668
3,688
4,298
2,861
3,493
3,711
5,740
6,410
4,932
6,775
6,149
6,1496,7754,9326,4105,7403,7113,4932,8614,2983,6883,6683,3132,9153,8873,4474,9685837392,1233,3703,0782,5342,2309,0209,2409,0904,1403,0205,0804,8804,7403,5904,1303,1702,7702,6302,3402,658
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
135
68
0
0
1,323
956
405
88
92
826
840
855
870
885
901
917
933
949
966
983
98396694993391790188587085584082692884059561,3230068135000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,298
927
371
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000003719271,2980000000000000000000000
       Accounts payable 
1,048
920
1,210
500
590
1,020
430
530
590
560
470
1,190
230
290
7,020
430
385
441
1,676
60
147
263
2,650
915
1,913
914
1,853
1,403
928
954
541
392
456
1,586
4,081
1,852
2,504
2,434
2,4342,5041,8524,0811,5864563925419549281,4031,8539141,9139152,650263147601,6764413854307,0202902301,1904705605905304301,0205905001,2109201,048
       Other Current Liabilities 
1,610
1,420
1,420
2,270
2,580
3,110
3,160
4,210
4,290
4,520
2,550
2,950
8,860
8,950
2,000
1,800
2,149
2,637
1,694
2,063
592
320
996
1,575
1,569
1,754
1,316
1,419
1,890
2,489
1,450
2,216
2,354
3,237
1,396
2,131
3,305
2,732
2,7323,3052,1311,3963,2372,3542,2161,4502,4891,8901,4191,3161,7541,5691,5759963205922,0631,6942,6372,1491,8002,0008,9508,8602,9502,5504,5204,2904,2103,1603,1102,5802,2701,4201,4201,610
   > Long-term Liabilities 
11,903
0
0
50
80
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
387
379
395
999
974
6,819
6,603
6,384
6,160
5,933
5,702
5,467
5,227
4,984
4,736
4,484
4,4844,7364,9845,2275,4675,7025,9336,1606,3846,6036,8199749993953793870000000000000000080500011,903
       Warrants
126,169
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000126,169
> Total Stockholder Equity
9,618
82,460
78,290
73,760
69,030
63,410
57,750
50,930
44,520
38,440
33,000
29,490
39,470
34,740
29,490
25,620
24,871
20,443
14,690
9,477
51,913
6,392
64,742
59,431
194,626
199,243
188,126
178,405
170,406
161,914
152,235
145,458
139,178
102,083
94,768
85,225
76,956
68,321
68,32176,95685,22594,768102,083139,178145,458152,235161,914170,406178,405188,126199,243194,62659,43164,7426,39251,9139,47714,69020,44324,87125,62029,49034,74039,47029,49033,00038,44044,52050,93057,75063,41069,03073,76078,29082,4609,618
   Common Stock
-35,416
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
19
19
19
19
2
0
6
6
11
11
11
11
11
11
11
11
11
11
11
11
11
11
1111111111111111111111111111660219191919202020202020202020202020202020-35,416
   Retained Earnings -200,384-190,163-180,303-169,009-159,964-120,997-113,306-104,767-94,012-83,784-73,007-60,225-46,760-37,952-29,982-22,842-225,462-10,713-222,316-217,001-210,470-205,211-200,700-195,820-189,740-184,190-171,880-166,280-159,780-152,820-145,710-137,800-131,250-124,910-119,530-114,450-109,870-116,540
   Capital Surplus 
0
192,324
192,731
193,266
193,919
194,651
195,529
196,607
197,310
198,201
199,259
201,366
202,113
202,953
203,774
204,780
208,536
209,366
210,486
210,587
210,683
213,388
87,578
89,407
0
245,992
248,504
251,502
0
0
0
0
0
0
264,235
0
0
0
000264,235000000251,502248,504245,992089,40787,578213,388210,683210,587210,486209,366208,536204,780203,774202,953202,113201,366199,259198,201197,310196,607195,529194,651193,919193,266192,731192,3240
   Treasury Stock00000000000000000000000000000000000000
   Other Stockholders Equity 
126,169
192,330
192,720
193,270
193,900
194,660
195,510
196,600
197,300
198,200
199,260
201,370
202,124
224,480
203,771
204,776
208,532
230,884
210,483
210,583
41,437
213,388
87,578
89,407
232,567
245,992
248,504
251,502
254,218
256,126
257,933
259,875
261,294
262,724
264,235
265,853
267,273
268,725
268,725267,273265,853264,235262,724261,294259,875257,933256,126254,218251,502248,504245,992232,56789,40787,578213,38841,437210,583210,483230,884208,532204,776203,771224,480202,124201,370199,260198,200197,300196,600195,510194,660193,900193,270192,720192,330126,169



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-341
Gross Profit-341-341
 
Operating Income (+$)
Gross Profit-341
Operating Expense-43,272
Operating Income-43,613-43,613
 
Operating Expense (+$)
Research Development24,785
Selling General Administrative18,624
Selling And Marketing Expenses137
Operating Expense43,27243,546
 
Net Interest Income (+$)
Interest Income2,999
Interest Expense-0
Other Finance Cost-107
Net Interest Income2,892
 
Pretax Income (+$)
Operating Income-43,613
Net Interest Income2,892
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-40,420-46,806
EBIT - interestExpense = -43,613
-40,761
-40,420
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-43,613-40,420
Earnings Before Interest and Taxes (EBITDA)-43,272
 
After tax Income (+$)
Income Before Tax-40,420
Tax Provision-0
Net Income From Continuing Ops-69,166-40,420
Net Income-40,420
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses43,613
Total Other Income/Expenses Net3,193-2,892
 

Technical Analysis of Protara Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Protara Therapeutics Inc. The general trend of Protara Therapeutics Inc is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Protara Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Protara Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.4 < 4.95 < 5.24.

The bearish price targets are: 2.63 > 2.5918 > 1.8.

Tweet this
Protara Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Protara Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Protara Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Protara Therapeutics Inc. The current macd is -0.25455916.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Protara Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Protara Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Protara Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Protara Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartProtara Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Protara Therapeutics Inc. The current adx is 25.02.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Protara Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Protara Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Protara Therapeutics Inc. The current sar is 4.04312813.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Protara Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Protara Therapeutics Inc. The current rsi is 26.23. The current phase is Oversold in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bull market: Short-term excessive selling, potential for rebound. Consider buying at a perceived discount, watch for reversal signs. +1
  • Trending down: The RSI is trending down. -1
Protara Therapeutics Inc Daily Relative Strength Index (RSI) ChartProtara Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Protara Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Protara Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Protara Therapeutics Inc Daily Stochastic Oscillator ChartProtara Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Protara Therapeutics Inc. The current cci is -127.68421903.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Protara Therapeutics Inc Daily Commodity Channel Index (CCI) ChartProtara Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Protara Therapeutics Inc. The current cmo is -68.56435372.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Protara Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartProtara Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Protara Therapeutics Inc. The current willr is -98.81889764.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Protara Therapeutics Inc Daily Williams %R ChartProtara Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Protara Therapeutics Inc.

Protara Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Protara Therapeutics Inc. The current atr is 0.32028004.

Protara Therapeutics Inc Daily Average True Range (ATR) ChartProtara Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Protara Therapeutics Inc. The current obv is -8,912,544.

Protara Therapeutics Inc Daily On-Balance Volume (OBV) ChartProtara Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Protara Therapeutics Inc. The current mfi is 86.40.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Protara Therapeutics Inc Daily Money Flow Index (MFI) ChartProtara Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Protara Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-16ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-09BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Protara Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Protara Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.225
Ma 20Greater thanMa 503.623
Ma 50Greater thanMa 1003.718
Ma 100Greater thanMa 2002.823
OpenGreater thanClose2.820
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Protara Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Protara Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Protara Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Protara Therapeutics Inc

I send you an email if I find something interesting about Protara Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Protara Therapeutics Inc.

Receive notifications about Protara Therapeutics Inc in your mailbox!